Cargando…
Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
Denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand, reduces skeletal-related events (SREs) and is approved for solid tumors with bone metastases. We studied long-term denosumab efficacy and safety because real-world data is scarce. This single-arm, single-center retrospec...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209178/ https://www.ncbi.nlm.nih.gov/pubmed/37225727 http://dx.doi.org/10.1038/s41598-023-35308-z |